Effects of Primary Mast Cell Disease on Hemostasis and Erythropoiesis

Int J Mol Sci. 2021 Aug 20;22(16):8960. doi: 10.3390/ijms22168960.

Abstract

Mast cell disease is an epigenetically and genetically determined disease entity with very diverse clinical manifestations in potentially every system and tissue due to inap pro priate release of variable subsets of mast cell mediators together with accumulation of either morphologically normal or altered mast cells. Easy bruising, excessive bleeding, and aberrancies of erythropoiesis can frequently be observed in patients with mast cell disease. A thorough history, including a family history, will guide the appropriate work-up, and laboratory evaluations may provide clues to diagnosis. In recent years, our understanding of the involvement of coagulation and anticoagulant pathways, the fibrinolytic system, and erythropoiesis in the pathophysiology of mast cell disease has increased considerably. This review summarizes current knowledge of the impact of the disturbed hemostatic and erythropoietic balance in patients with mast cell disease and describes options of treatment.

Keywords: bleeding; erythropoiesis; fibrinolysis; hemostasis; heparin; mast cell disease.

Publication types

  • Review

MeSH terms

  • Anticoagulants / pharmacology
  • Blood Coagulation / drug effects
  • Erythropoiesis / drug effects
  • Erythropoiesis / physiology*
  • Fibrinolysis / drug effects
  • Fibrinolytic Agents / pharmacology
  • Hemostasis / drug effects
  • Hemostasis / physiology*
  • Heparin / pharmacology
  • Humans
  • Mastocytosis / blood*
  • Mastocytosis / immunology
  • Mastocytosis / physiopathology

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Heparin